Pfizer, Moderna, J&J and AstraZeneca assess omicron's effect on their COVID-19 vaccines Thermo Fisher, Qiagen and other COVID-19 test makers prepare for oncoming omicron variant Biden dismisses need for more lockdowns as new COVID-19 variant sparks travel restrictions 'What it takes': Beyond the headlines, women are pushing groundbreaking new Alzheimer's treatments forward Novo Nordisk, Sanofi and Eli Lilly cut insulin prices and lose share in China's latest cost squeeze Labor shortages impacting care for patients with disabilities. Here's how some organizations are tackling the problem Is molnupiravir a turkey? Merck slips out drop in efficacy of COVID-19 antiviral over Thanksgiving period Repealing Trump-era breakthrough device coverage limits access to 'life-changing treatments,' lawmakers say Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron GE Healthcare doubles down on AI with new product launches, partnerships with Optellum and Cambridge UnitedHealth Group taps Wilson as new chief medical officer Ocugen COVID shot will have to wait for US market as FDA slaps clinical hold on phase 3 trial BD ramps up tech development with new science chief, scientific advisory board Featured Story By Kevin Dunleavy Producers of the world's top COVID-19 vaccines say they are moving quickly to test their shots against the new omicron variant. They also are developing shots tailored to the new strain. Moderna said it has a three-pronged strategy to address the threat. read more |
| |
---|
| | The PerkinElmer Lead Discovery Premium Biotech Bundle empowers you to find and understand trends and outliers in your data to ensure successful candidate selection. On the AWS Cloud, affordable, easy to deploy. Learn more. | Top Stories By Conor Hale With the omicron variant on the horizon, diagnostic companies are racing to determine whether the coronavirus’ latest mutations will hinder the performance of their screening tests. Companies including Thermo Fisher Scientific, Qiagen and Co-Diagnostics have stated that their PCR tests are not affected by the new strain. read more By Robert King President Joe Biden downplayed the need for new lockdowns due to the omicron variant as the WHO looks for more answers on the variant's impact. read more By Annalee Armstrong As Fierce Biotech reported out the aftermath of the controversial approval of Biogen’s Aduhelm, we discovered a common thread at many of the top pharma companies who are working on the most advanced treatments in development: women. We wanted to know—how have they kept going? read more By Angus Liu On the centennial of the discovery of insulin, China decided a round of price cuts on the diabetes therapy is due. As a result, foreign companies Novo Nordisk, Sanofi and Eli Lilly are taking a beating in the key market. read more By Anastassia Gliadkovskaya The turnover rate among support staff for people living with intellectual or developmental disabilities continues to climb, despite people with these disabilities being significantly more at risk of dying from COVID-19. read more By Nick Paul Taylor The efficacy of Merck’s COVID-19 antiviral has fallen sharply. While most Americans were sleeping off Thanksgiving, Merck revealed the relative risk reduction fell from 50% to 30% in the final analysis of its phase 3 data, sending its stock sliding down. read more By Dave Muoio Sixty-one bipartisan lawmakers told CMS Administrator Chiquita Brooks-LaSure that they "do not support" the repeal of the Medicare Coverage of Innovative Technology final rule, citing patients' reduced access to novel products. read more By Fraiser Kansteiner After Amgen earlier this year suffered a third consecutive loss in its high-profile PCSK9 patent feud with Sanofi and Regeneron, the company faced two choices: appeal further or drop the issue. Not content to play sitting duck, Amgen has asked the Supreme Court to step in and review the case. read more By Andrea Park As GE prepares to spin off its healthcare business into a separate entity, the soon-to-be standalone company is forging ahead in its quest to develop a broad range of artificial intelligence tools designed to overhaul and revamp existing hospital practices. read more By Heather Landi UnitedHealth Group's Margaret-Mary Wilson, M.D., is stepping into the role of chief medical officer to lead the company's clinical innovations, focusing particularly on improving health equity. read more By Kyle LaHucik It was a black Friday indeed for Ocugen, which revealed in the early morning hours after Thanksgiving that the FDA placed a clinical hold on its COVID-19 vaccine. read more By Andrea Park If BD’s ongoing hiring spree is any indication, the medtech giant—which recently reported nearly 20% growth in revenue for its fiscal year 2021—seems to be aiming to make an even bigger splash in 2022. read more |